fd-001

HBV Infection

Shanghai Zhongshan HospitalN/AActive

D

30/ 100

Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence: 15/ 100
Competitive Position: 95/ 100

Competitive context

22 Active assets in the HBV Infection cohort.

Asset / Sponsor	Phase	Rating
Entecavir Sun Yat-sen University	Phase 4	BBB
Lamivudine Fudan University	Phase 4	BBB
tenofovir Ruijin Hospital	Phase 4	BB
Hepatitis B Virus Vaccine Eunice Dube	Phase 4	BB
TENOFOVIR BIS(ISOPROPYLOXYCARBONYLOXYMETHYL) ESTER West China Hospital	Phase 4	BB

View all 45 →

Same molecule, other indications

fd-001 is also rated in:

non-Hodgkin lymphomaDormant

CC

Indicative ·

43 / 100

acute myeloid leukemiaDormant

C

Indicative ·

39 / 100

hepatocellular carcinomaDormant

D

Indicative ·

30 / 100

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.